202P eIF4E inhibition exhibits anti-tumor activity and re-sensitizes acquired resistant KRAS G12C NSCLC to KRAS inhibitors.
| Autor: | Truong, A.S.1 (AUTHOR), Thompson, S.E.1 (AUTHOR), Pavana, R.K.1 (AUTHOR), Changalvala, R.V.1 (AUTHOR), Sorrrentino, J.A.1 (AUTHOR), Friedersdorf, M.B.1 (AUTHOR) |
|---|---|
| Zdroj: | Annals of Oncology. 2024 Supplement 2, Vol. 35, pS298-S298. 1p. |
| Databáze: | Academic Search Ultimate |
| Externí odkaz: |
|